Related Experiment Video
Updated: Aug 9, 2026

Experimental Autoimmune Uveitis: An Intraocular Inflammatory Mouse Model
Published on: January 12, 2022
Favorable response to high-dose infliximab for refractory childhood uveitis
Philip Kahn1, Michael Weiss, Lisa F Imundo
1Morgan Stanley Children's Hospital of New York-Presbyterian, Columbia University Medical Center, New York, New York 10032, USA.
Objective:
Uveitis in children most commonly is associated with juvenile idiopathic arthritis. In addition to topical glucocorticoids, treatment may include systemic immunosuppressive agents. Tumor necrosis factor alpha (TNF-alpha) has been implicated in the pathogenesis of uveitis; therefore, TNF-alpha blockade seems to be a reasonable therapeutic option to investigate. We report successful treatment of children with uveitis using infliximab.
Study Design:
A retrospective study of our complete experience using infliximab for the treatment of childhood uveitis was conducted.
Participants:
Seventeen children (14 females, 3 males) with chronic uveitis were administered high-dose infliximab (10-20 mg/kg/dose).
Main Outcome Measures:
Our main outcome measure was the ability to eliminate all signs of intraocular inflammation.
Results:
All 17 patients demonstrated a dramatic, rapid response, with no observed inflammation in 13 patients after the second infusion, and 4 patients requiring 3 to 7 infusions to achieve disease quiescence. Additional immunosuppressives and topical glucocorticoids were tapered when patients achieved no intraocular inflammation.
Conclusions:
In this series, high-dose infliximab was a rapidly effective, well-tolerated therapeutic agent for the treatment of chronic, medically refractory, noninfectious uveitis.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Hypersensitivity Reactions: Immune-Complex Reactions
Hypersensitivity Reactions: Cytolytic Reactions